BioLine Rx (FRA:YP2) Total Payout Yield %: -24.84 (As of Jul. 09, 2026)


FRA:YP2 BioLine Rx Ltd FRA:YP2
21 GF Score
Price €2.52
! 5 Warning Signs
View Full Analysis

What is BioLine Rx Total Payout Yield %?

BioLine Rx FRA:YP2 21 Total Payout Yield % is -24.84 as of Jul. 09, 2026. GuruFocus rates FRA:YP2 with a GF Score™ of 21/100. The stock has 5 warning signs investors should review.

Total Payout Yield % is the percent a company has paid to its shareholders through net repurchases of shares and dividends based on its Market Cap. It is a measure of shareholder return.

BioLine Rx's current Total Payout Yield % is -24.84%.

BioLine Rx Total Payout Yield % Explanation

Similar to Dividend Yield, Total Payout Yield % is a measurement of shareholder return. Dividends is not the only way that companies are able to distribute their excess cash back to the shareholders. The other way to distribute the cash is a stock repurchase. The stock repurchase buys back the company's own shares from the marketplace. This results in a reduced number of oustanding shares, making each share worth a greater percentage of the corporation.

BioLine Rx Total Payout Yield % Related Terms

BioLine Rx Total Payout Yield % Historical Data

* Premium members only.

The historical data trend for BioLine Rx's Total Payout Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioLine Rx Total Payout Yield % Chart

BioLine Rx Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Payout Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -52.27 -42.37 -12.92 -108.20 -122.29

BioLine Rx Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Payout Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -356.94 -77.99 -9.02 0.00 0.00

FRA:YP2 vs VRTX, REGN, ALNY: Total Payout Yield % Comparison

For the Biotechnology subindustry, BioLine Rx's Total Payout Yield %, along with its competitors' market caps and Total Payout Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioLine Rx Total Payout Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLine Rx's Total Payout Yield % distribution charts can be found below:

* The bar in red indicates where BioLine Rx's Total Payout Yield % falls into.


FRA:YP2
21GF Score
BioLine Rx Ltd FRA:YP2
Total Payout Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioLine Rx Total Payout Yield % Calculation

Total Payout Yield % is a measure of shareholder return.

BioLine Rx's Total Payout Yield % for the fiscal year that ended in Dec. 2025 is calculated as

Total Payout Yield %=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Market Cap
=- (0 + 11.865 + 0) / 9.70273
=-122.29%

BioLine Rx's annualized Total Payout Yield % for the quarter that ended in Mar. 2026 is calculated as

Total Payout Yield %=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) * Annualized Factor / Market Cap
=- (0 + 0 + 0) * 4 / 7.457614
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Payout Yield % →
What does a Total Payout Yield % of -24.84 mean?
BioLine Rx (FRA:YP2) has a Total Payout Yield % of -24.84 as of Jul. 09, 2026. Total Payout Yield is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Market Cap. View historical data on BioLine Rx and its competitors.
Is BioLine Rx's Total Payout Yield % too high?
BioLine Rx's current Total Payout Yield % is -24.84. Overall, BioLine Rx has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does BioLine Rx's Total Payout Yield % compare to VRTX and REGN?
BioLine Rx's Total Payout Yield % of -24.84 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Yield % for a Biotechnology company?
A good Total Payout Yield % depends on the Biotechnology industry context. However, Total Payout Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Yield % mean?
A high Total Payout Yield % can signal that a stock is expensive relative to its fundamentals. Total Payout Yield is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Market Cap. View historical data on BioLine Rx and its competitors. BioLine Rx's current Total Payout Yield % is -24.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLine Rx stock overvalued right now?
BioLine Rx (FRA:YP2) has a current Total Payout Yield % of -24.84. The current Total Payout Yield % is -24.84. BioLine Rx's overall GF Score™ is 21/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Yield % calculated?
Total Payout Yield % is calculated from a company's financial statements. For BioLine Rx (FRA:YP2), the current Total Payout Yield % is -24.84 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioLine Rx Business Description

Other Exchanges BLRX:USABLRX:Israel
Address 2 HaMa’ayan Street, Modi’in, ISR, 7177871
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
21GF Score

Get the complete analysis for FRA:YP2

Total Payout Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.52
Price